488 related articles for article (PubMed ID: 19459851)
1. Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia.
Kizaka-Kondoh S; Konse-Nagasawa H
Cancer Sci; 2009 Aug; 100(8):1366-73. PubMed ID: 19459851
[TBL] [Abstract][Full Text] [Related]
2. Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells.
Kudo T; Ueda M; Kuge Y; Mukai T; Tanaka S; Masutani M; Kiyono Y; Kizaka-Kondoh S; Hiraoka M; Saji H
J Nucl Med; 2009 Jun; 50(6):942-9. PubMed ID: 19443598
[TBL] [Abstract][Full Text] [Related]
3. Construction of mutant TKGFP for real-time imaging of temporal dynamics of HIF-1 signal transduction activity mediated by hypoxia and reoxygenation in tumors in living mice.
Hsieh CH; Kuo JW; Lee YJ; Chang CW; Gelovani JG; Liu RS
J Nucl Med; 2009 Dec; 50(12):2049-57. PubMed ID: 19910419
[TBL] [Abstract][Full Text] [Related]
4. Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression.
O'Donnell JL; Joyce MR; Shannon AM; Harmey J; Geraghty J; Bouchier-Hayes D
Cancer Treat Rev; 2006 Oct; 32(6):407-16. PubMed ID: 16889900
[TBL] [Abstract][Full Text] [Related]
5. Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer.
Kizaka-Kondoh S; Itasaka S; Zeng L; Tanaka S; Zhao T; Takahashi Y; Shibuya K; Hirota K; Semenza GL; Hiraoka M
Clin Cancer Res; 2009 May; 15(10):3433-41. PubMed ID: 19417024
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia in head and neck cancer: how much, how important?
Janssen HL; Haustermans KM; Balm AJ; Begg AC
Head Neck; 2005 Jul; 27(7):622-38. PubMed ID: 15952198
[TBL] [Abstract][Full Text] [Related]
7. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.
Ebbesen P; Pettersen EO; Gorr TA; Jobst G; Williams K; Kieninger J; Wenger RH; Pastorekova S; Dubois L; Lambin P; Wouters BG; Van Den Beucken T; Supuran CT; Poellinger L; Ratcliffe P; Kanopka A; Görlach A; Gasmann M; Harris AL; Maxwell P; Scozzafava A
J Enzyme Inhib Med Chem; 2009 Apr; 24 Suppl 1():1-39. PubMed ID: 19330638
[TBL] [Abstract][Full Text] [Related]
8. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography.
Aboagye EO; Kelson AB; Tracy M; Workman P
Anticancer Drug Des; 1998 Sep; 13(6):703-30. PubMed ID: 9755726
[TBL] [Abstract][Full Text] [Related]
9. [Recent progress in the study on antitumor drugs targeting hypoxia-inducible factor-1].
Wang JJ; Li J; Geng MY
Yao Xue Xue Bao; 2008 Jun; 43(6):565-9. PubMed ID: 18822956
[TBL] [Abstract][Full Text] [Related]
10. HIF gene expression in cancer therapy.
Chan DA; Krieg AJ; Turcotte S; Giaccia AJ
Methods Enzymol; 2007; 435():323-45. PubMed ID: 17998061
[TBL] [Abstract][Full Text] [Related]
11. [Can tumor hypoxia be turned into a chemotherapeutic advantage?].
Trédan O; Grantab R; Dumontet C
Bull Cancer; 2008 May; 95(5):528-34. PubMed ID: 18541517
[TBL] [Abstract][Full Text] [Related]
12. The hypoxic tumor microenvironment and gene expression.
Leo C; Giaccia AJ; Denko NC
Semin Radiat Oncol; 2004 Jul; 14(3):207-14. PubMed ID: 15254863
[TBL] [Abstract][Full Text] [Related]
13. Tumor hypoxia in cancer therapy.
Brown JM
Methods Enzymol; 2007; 435():297-321. PubMed ID: 17998060
[TBL] [Abstract][Full Text] [Related]
14. The role of hypoxia-induced factors in tumor progression.
Vaupel P
Oncologist; 2004; 9 Suppl 5():10-7. PubMed ID: 15591418
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
Xia Y; Choi HK; Lee K
Eur J Med Chem; 2012 Mar; 49():24-40. PubMed ID: 22305612
[TBL] [Abstract][Full Text] [Related]
16. Regulation of hypoxia-inducible factors during inflammation.
Frede S; Berchner-Pfannschmidt U; Fandrey J
Methods Enzymol; 2007; 435():405-19. PubMed ID: 17998066
[TBL] [Abstract][Full Text] [Related]
17. Modulation of cell death in the tumor microenvironment.
Wouters BG; Koritzinsky M; Chiu RK; Theys J; Buijsen J; Lambin P
Semin Radiat Oncol; 2003 Jan; 13(1):31-41. PubMed ID: 12520462
[TBL] [Abstract][Full Text] [Related]
18. STAT1 represses hypoxia-inducible factor-1-mediated transcription.
Hiroi M; Mori K; Sakaeda Y; Shimada J; Ohmori Y
Biochem Biophys Res Commun; 2009 Oct; 387(4):806-10. PubMed ID: 19646959
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia in cancer: significance and impact on clinical outcome.
Vaupel P; Mayer A
Cancer Metastasis Rev; 2007 Jun; 26(2):225-39. PubMed ID: 17440684
[TBL] [Abstract][Full Text] [Related]
20. Impact of supervised gene signatures of early hypoxia on patient survival.
Seigneuric R; Starmans MH; Fung G; Krishnapuram B; Nuyten DS; van Erk A; Magagnin MG; Rouschop KM; Krishnan S; Rao RB; Evelo CT; Begg AC; Wouters BG; Lambin P
Radiother Oncol; 2007 Jun; 83(3):374-82. PubMed ID: 17532074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
